Saturday 17 October 2026
Export LAB’s income statement to Excel — free account
Standard BioTools Inc.
LAB Healthcare Medical Devices
In the quarter to June 2026, revenue fell 7.62%, EPS grew 22.2%, free cash flow grew 52.8% and total debt was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.63
0.03
−4.55%
Follow LAB
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 4.60 | 3.73 |
P/S ratio |
7.97 | 5.72 | 4.14 | 3.79 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(22.40) | (410.49) | (7.66) | (31.09) | |
P/B ratio |
1.24 | 1.15 | 0.64 | 0.59 | |
Price to Tangible BV |
1.91 | 1.72 | 0.85 | 0.80 | |
EV/Sales |
4.93 | 3.59 | (1.08) | (1.78) | |
EV/EBITDA |
0.00 | 0.00 | 1.03 | 1.62 | |
EV/Operating CF |
(3.53) | (4.12) | 1.02 | 1.88 | |
EV/FCF |
(2.93) | (3.43) | 0.92 | 1.69 | |
Quick Ratio |
1.93 | 1.86 | 11.77 | 8.67 | |
Current Ratio |
4.38 | 4.19 | 12.36 | 9.10 | |
Net Debt/EBITDA |
6.08 | 7.86 | 38.81 | 18.81 | |
Debt/Assets |
0.06% | 0.05% | 0.05% | 0.05% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.10 | 0.14 | 0.14 | 0.14 | |
Operating CF/Net income |
0.64 | (0.06) | (0.37) | 0.39 | |
Capex/Depreciation |
(0.97) | (0.57) | (0.73) | (5.21) | |
Interest Coverage |
(3,293.80) | (1,540.25) | — | — | |
Research and Development Expense of Revenue |
32.51% | 33.49% | 10.01% | 9.83% | |
Selling, General and Administrative Expense of Revenue |
136.02% | 106.48% | 87.99% | 81.52% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
43.34% | 24.14% | 41.73% | 20.15% | |
Graham Net Nets |
0.67 | 0.64 | 1.24 | 1.34 | |
Graham Number |
0.00 | 0.00 | 2.55 | 2.62 | |
Earnings Yield |
(26.15%) | (15.63%) | 21.74% | 26.83% | |
Free Cash Flow Yield |
(21.11%) | (18.27%) | (28.30%) | (27.82%) | |
Revenue per Share |
0.05 | 0.06 | 0.05 | 0.05 | |
Operating CF per Share |
(0.06) | 0.00 | (0.12) | (0.03) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.06) | 0.00 | (0.12) | (0.03) | |
Cash per Share |
0.51 | 0.49 | 1.17 | 1.22 | |
Shareholders Equity per Share |
1.04 | 1.11 | 1.45 | 1.38 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.04 | 1.11 | 1.45 | 1.38 | |
Free Cash Flow |
(23.09) | (1.67) | (47.17) | (10.65) | |
Working Capital |
364.47 | 345.96 | 479.25 | 460.07 | |
Capital Expenditures |
(0.89) | (0.48) | (0.57) | (0.34) | |
Net Current Asset Value |
332.46 | 310.80 | 443.46 | 429.62 | |
EV/EBIT |
0.00 | 0.00 | 0.97 | 1.58 | |
Capex to Sales |
0.05 | 0.02 | 0.03 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
24.43 | 14.09 | 38.56 | 15.18 | |
Average Payables |
8.77 | 5.23 | 9.89 | 8.44 | |
Average Inventory |
34.03 | 20.36 | 30.36 | 20.64 | |
Average Assets |
610.59 | 590.05 | 609.36 | 592.09 | |
Average Common Equity |
444.50 | 448.01 | 507.86 | 482.25 |
Columns are period end dates